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Epilepsy is one of the major neurological dis-
orders. In fact, it is a syndrome of different cerebral
disorders. This syndrome is characterized by parox-
ysmal, excessive and hypersynchronous discharges
of large number of neurons, causing fluctuations in
brain electrochemical balance. About 1% of the
entire world population is suffering from seizures
being the effect of the disorders. There are many
antiepileptic drugs (AEDs), such as gabapentin,
lamotrigine, levetiracetam, and zonisamide, howev-
er, they cause adverse effects, among which there
are headache, dizziness, sleepiness, ataxia, double
vision, and cerebellum atrophy, nausea, vomiting,
etc. (1). Some drugs cause specific adverse effects
such as aplastic anemia (felbamate) (2) or cystic
ovaries or hirsutism (valproic acid) (3). Moreover,
many patients exhibit seizures resistant to pharma-
cological treatment, which constitutes about 25% of
all cases. Such conditions have large influence on
psycho-social, intellectual, behavioral as well as
financial aspects of life.
Antiepileptic drugs belong to many chemical
groups and therefore they have different mecha-
nisms of action. It is a serious aspect of epilepsy that
epileptic attacks are often managed by two AEDs,
and once they are no more effective, a third one may
be introduced. It is not surprising, if it is for interac-
tions that are due to influence on liver microsomal
enzymes. For instance, valproic acid inhibits lamot-
rigine glucuronidation, which may result in delirium
(4). A separate problem is epilepsy in patients like
women of child-bearing age (5), children (6), and
generally patients suffering from accompanying dis-
eases, such as depression or migraine (7, 8).
Although several new antiepileptic drugs have
been approved in the recent years or are in the
process of being approved, e.g. lamotrigine, felba-
mate, zonisamide, levetiracetam, rufinamide, sero-
tolide, etc. (9), there is no AED that would act
specifically on each kind of seizures and would be
completely safe. Different chemical groups of AEDs
are specific for certain kinds of seizures. A well cho-
sen drug should completely eliminate seizure
events, have a large protection index (PI), low toxi-
city, and it ought to be well tolerated, absorbed eas-
ily from the digestive tract and it should be easy to
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monitor its concentration. Since there is no drug that
would fulfill all these criteria, there are strong prem-
ises for further research in this field.
In previous studies (10-12) we reported anti-
convulsant activity of some appropriate amido- and
aminoalkanols which were examined according to
the Anticonvulsant Screening Project (ASP, National
Institute of Neurological and Communicative
Disorders and Stroke NINCDS, Bethesda, USA).
Some of them displayed protection against MES-
induced seizures and low neurotoxicity. From the
preliminary assay data, it was ascertained that anti-
convulsant activity was associated mainly with one
of the aminoalkanol types. The most promising com-
pounds were: (R,S)-2-(6-chloro-2-xanthonemeth-
yl)amino-1-propanol (10), (S)-(+)-2-[(2,6-dimeth-
yl)phenoxyethyl]amino-1-butanol (11) and 2-[4-
(benzyloxy)benzoyl]-2N-methylamino-1-ethanol
(12). Their anti-MES ED50 (mg/kg, mice, i.p.) values
and protective indices (PI) are presented in Figure 1.
Moreover, 2-(4-benzyloxy)benzoyl-2N-methy-
laminoethanol was demonstrated to be effective
against the subcutaneous pentylenetetrazole induced
seizures (ScMet) with ED50 = 142.98 mg/kg, and PI
(ScMet) = 0.919 (mice, i.p.). Such anticonvulsant
activity of the appropriate amino- or amidoalkanols
drew our attention onto other related derivatives,
including different aminoalkanols also with a chiral
center. In designing new aminoalkanol derivatives, a
general pattern derived from the reference literature
has been adopted. 
This report describes synthesis and preliminary
evaluation of anticonvulsant activity of a series of
[4-(benzyloxy)benzoyl]-aminoalkanols [I-V] and
their alkanolamine analogues [VI-XVII] (Table 1);
some of the latter [VI, XI, XVII] are amine ana-
logues of formerly examined amides (12). 
RESULTS AND DISCUSSION
Chemistry
As a result of our investigations, we present the
synthesis of the new aminoalkanol derivatives, that
are based on the formula included in Tables 1, 2.
The synthesis of the appropriate alkanolamides
I-V was carried out according to Scheme 1, by N-
acylation of appropriate aminoalkanol with 4-(ben-
zyloxy)benzoyl chloride in two-phase system
(toluene / H2O / K2CO3) according to well-known
procedures (12). Yields of the reactions were within
the range of 50-60%.
Two common methods were used in order to
prepare VI-XVII. The first method was based on the
reduction of the amides [I-V] to the appropriate
amines [VII, XII-XIII, and XV-XVI] and the sec-
ond one was N-alkylation of appropriate aminoalka-
nols by 4-(benzyloxy)benzyl chloride in the pres-
ence of anhyd. K2CO3 in toluene solution, which
gave VI, VIII-XI, and XVII (yield 65 ñ 70%)
(Scheme 1). The reduction of the amides was per-
formed using LiAlH4 in diethyl ether solution under
nitrogen atmosphere at room temperature (yield 40-
60%). The separated products [VII, XII-XIII, and
XV-XVI] were purified with the use of planar circu-
lar chromatography (chromatotron), where the solid
phase constituted silica gel 60 PF254 (Merck) and the
liquid phase was CHCl3 / CH3OH (49 : 1, v/v), and
then recrystallized from n-heptane. Change of the
secondary amine group of XI into a tertiary one of
XIV was performed by reductive N-methylation
(HCHO / HCOOH) (Scheme 1). Some of the
obtained amines were isolated and characterized as
bases [VI base, VIII base, XI-XIII, and XVII] and
their salts [VI, VIII, XIa-XIIIa, and XVIIa] or as
bases [VII, IX-X, XV, and XVI] or as a hydrochlo-
ride [XIV]. The appropriate bases were converted
into hydrochloride salts in ethyl acetate with an
excess of EtOH saturated with HCl. 
The appropriate enantiomers were recrystal-
lized to constant rotation value [II, III, V] from
Figure 1. Chemical structures, ED50 and protective indices of the
most promising compounds from the previous studies (10-12).
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toluene n-heptane (1 : 1) and [XII-XIII, XVI] from
n-heptane. Recrystallization of racemates I, IV was
performed from toluene / heptane (1 : 1, v/v), VI,
VIII, XIa-XIIIa, XIV and XVIIa from a mixture of
ethyl acetate / EtOH (3 : 1, v/v) and VII, IX-XI, XV,
and XVII from n-heptane. The necessary 4-(benzy-
loxy)benzoyl and 4-(benzyloxy)benzyl chlorides
were formerly prepared by heating the correspon-
ding acid or alcohol, under reflux with thionyl chlo-
ride. The raw product was used in the amination
process. The purity of I-XVII was checked by TLC
using the developing systems: methanol / ethyl
acetate (1 : 1, v/v) or methanol and all compounds
were evaluated on the basis of elemental and spec-
tral analyses (IR, 1H-NMR). Moreover, COSY and
HSQC spectra were taken in order to determine the
structure of XI. The structures and calculated parti-
tion coefficient (Log Pcomb., Pallas 3.1.1.2) of I-XVII
are summarized in Table 1 and 2. 
All the obtained aminoalkanols with exception
for VI, VIII and XIV (hydrochlorides) were tested
in anticonvulsant screens as bases.
Pharmacology
All compounds have been evaluated in prelim-
inary pharmacological testing according to the ASP
(NINCDS, Bethesda, MD, U.S.A). The procedures
have been described formerly (13, 14). Phase I stud-
ies involved three tests: maximal electroshock-
induced seizures (MES, mice, i.p.), subcutaneous
pentylenetetrazole-induced seizures (ScMet, mice,
i.p.), and neurological toxicity (TOX, mice, i.p.),
which was measured by the rotorod test. The results
of anticonvulsant assays are presented in Table 4. 
Selected compounds II-III and V were
advanced to phase VIa in which they were tested for
an oral activity in rats due to the ADD program.
Phase VIa includes MES, ScMet and TOX screens.
The results are presented in Table 5.
RESULTS AND DISCUSSION
As it is shown in Table 4, the protective activ-
ity in the MES test (mice, i.p.) was found for most
of the tested compounds, including all tested amides
[I-V]. Compounds III and V revealed activity at the
dose of 100 mg/kg (100% and 67% activity, respec-
tively) and they both were not toxic at the mentioned
dose. Moreover, I, II and IV were also active in the
ScMet test at the dose of 300 mg/kg (100%, 20%
and 60% activity, respectively). Compounds II and
III are enantiomers of formerly examined racemate
Scheme 1. Synthesis of the tested [4-(benzyloxy)benzoyl]- and [4-(benzyloxy)benzyl]-aminoalkanols [I-XVII].
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Table 1. Chemical structures, some physical data and Log Pcomb. of the tested 4-(benzyloxy)benzoyl derivatives [I-V] compared with known
AEDs.
Formula (M. w.)
Melting point [OC] Log Pcomb
Compound Z Rf (Pallas 3.1.1.2)
Yield
[α]
CBZ * - - 3.30













[α]54622.7= + 28.3O c)







[α]54622.7= ñ 27.3O c)













[α]58918.5= ñ 25.7O c)
[α]54620= ñ 30.0O c)
* Carbamazepine; ** Valproic Acid; a) toluene/heptane (1:1); b) CH3OH; c) c = 2%, CH3OH.
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Table 2. Chemical structures, some physical data, and Log Pcomb. of the synthesized 4-(benzyloxy)benzyl derivatives [VI-XVII].
Formula (M. w.)
Melting point [OC] Log Pcomb
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Table 2. cont.
Formula (M. w.)
Melting point [OC] Log Pcomb







[α]58922.7 = -15.1O d)













[α]58922.7 = +16.0O d)



























[α]58917.0= + 4.82O d)










a) ethyl acetate/EtOH (3:1, v/v); b) CH3OH/ethyl acetate (1:1, v/v); c) n-heptane; d) c = 1%, CH3OH; e) CH3OH.
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Table 3. The IR and 1H NMR spectral data of I, IV-XI, and XIV-XVII.
IR (KBr, cm-1)
Compd. νñ=OH and/or NH 1H NMR (δ ppm)
νñ=C=O
1.18 (t, J = 7 Hz, 3H, -CH2-CH3), 3.35 ñ 3.45 (m, 2H, -CH2-CH3), 3.62 ñ 
3400 3.72 (m, 2H, N-CH2-CH2-OH), 3.82 ñ 3.94 (m, 3H, N-CH2-CH2-OH and OH),
I 1616 5.15 (s, 2H, Ar-CH2-O), 6.98 (d, J = 8.5 Hz, 2H, C2,C6-C6H4), 7.30 ñ 7.45 (m,
7H, Ar: 5H, C6H5, 2H, C3,C5-C6H4)
1.51 (s, 6H, -C(CH3)2), 1.88 (t, J=5,6 Hz, J=5.3 Hz, 2H, CH2-CH2-OH), 3.90
IV 3331, (t, J=5.4 Hz, 2H, CH2-CH2-OH), 5.07 (s, 2H, Ar-CH2-O), 6.93 (d, J=9.0 Hz, 2H, 
1636 C2,C6ñC6H4) 7.34-7.40 (m, 6H, Ar, N-H), 7.70 (d, J=9Hz, 2H, C3,C5ñC6H4)
1.01 (dd, J=5.6 Hz, J=5.5 Hz, 6H, -CH(CH3)2), 1.97-2.06 (m, 1H, -
CH(CH3)2), 2.43 (s, 1H, -OH), 3.76-3.89 (m, 2H, -CH2-OH), 3.91-3.96 (m, 1H, 
V 3304 CH-CH2-OH), 5.11 (s, 2H, Ar-CH2-O), 6.27 (d, J=7.95 Hz, 1H, N-H), 6.99 (d, 
1631 J=2.05 Hz, 2H, C2,C6-C6H4), 7.33-7.44 (m, 5H, Ar), 7.74 (d, J=2.05 Hz, 2H, 
C3,C5-C6H4)
2.25 (s, 3H, N-CH3), 2.62 (t, J = 5.5 Hz, 2H, N-CH2-), 3.54 (s, 2H, Ar-CH2-N), 
VI 3167 3.65 (t, J = 5.5 Hz, 2H, -CH2-OH), 5.09 (s, 2H, Ar-CH2-O), 6.97 (d, J = 8.5 Hz, 
2H, C2,C6 ñ C6H4) 7.22 ñ 7.49 (m, 7H, Ar: 5H, C6H5, 2H, C3,C5-C6H4)
1.09 (t, J = 7 Hz, 3H, -CH3), 2.59 (q, J = 7 Hz, 2H, -CH2-CH3), 2.67 
(t, J = 5.5 Hz, 2H, N-CH2-), 3.59 (t, J = 5.5 Hz, 2H, -CH2-OH), 3.60 (s, 2H, Ar-
VII 3343, 3163
CH2-N), 5.09 (s, 2H, Ar-CH2-O), 6.97 (d, J = 8.5 Hz, 2H, C2,C6 ñ C6H4), 7.23 ñ 
7.49 (m, 7H, Ar: 5H, C6H5, 2H, C3,C5-C6H4)
1.76 (m, 2H, -CH2-CH2-CH2-), 2.84 (t, J=7.5 Hz, 2H, NH-CH2-CH2-CH2-), 3.44 
VIII 3335 (t, J=6.0 Hz, 2H, -CH2-CH2-OH), 3.99 (s, 2H, C6H4-CH2-NH), 5.11 (s, 2H, C6H5-
CH2-O), 6.98-7.47 (m, 10H: 9H-Ar: C6H5 and C6H4, 1H, NH)
(CDCl3) 1.15 (s, 6H, -C(CH3)2), 2.20 (br s, 2H, NH, OH), 3.34 (s, 2H, C6H4-CH2), 
IX 3331, 3298 3.62 (s, 2H, CH2-OH), 5.05 (s, 2H, C6H5-CH2), 6.93 (d, J=8.8 Hz, 2H, C2,C6-
C6H4), 7.25 (d, J=8.8 Hz, 2H, C3,C5-C6H4), 7.27-7.45 (m, 5H, C6H5)
1.60 ñ 1.73 (m, 4H, ñ CH2- CH2-), 2.69 (t, J = 5.5 Hz, 2H, N-CH2-), 2.97 (br s, 
2H, NH and OH), 3.59 (t, J = 5.5 Hz, 2H, -CH2-OH), 3,73 (s, 2H, Ar- CH2-N), 
X 3287
5.05 (s, 2H, Ar-CH2-O), 6.93 (d, J = 8.5 Hz, 2H, C2,C6-C6H4), 7.22 ñ 7.44 (m, 
7H, Ar: 5H, C6H5, 2H, C3,C5-C6H4)
0.96 (t, J = 7.4 Hz, 3H, -CH3), 1.53 (m, 2H, -CH2-CH3), 2.19 (br s, 2H, OH and 
NH), 2.65 ( m, 1H, NH-CH), 3.31 (dd, J2 = 10.6 Hz, J3 = 6.4 Hz, 1H, -CH2-OH),
XI 3263 3.65, (dd, J2 = 10.6 Hz, J3 = 4.0 Hz, 1H, -CH2-OH), 3.70 (d, J = 12.8 Hz, 1H, Ar-
CH2-N), 3.78 (d, J = 12.8 Hz, 1H, Ar-CH2-N), 5.10 (s, 2H, Ar-CH2-O), 6.98 (d, J
= 8.5 Hz, 2H, C2,C6-C6H4), 7.23 ñ 7.49 (m, 7H, Ar: 5H, C6H5, 2H, C3,C5-C6H4)
0.83 (t, J=7,2 Hz, 3H, -CH2-CH3), 1.22-1.42 (m, 2H, -CH2-CH3), 2.66-2.69 (s, 
3H, N-CH3), 2.78-3.16 (m, 2H, Ar-CH2-N), 3.16-3.78 (m, 2H, Ar-CH2-N), 3.75-
XIV 3231 3.98 (m, 1H, CH), 4.12-4.36 (m, 2H, CH2-OH), 5.11 (s, 2H, Ar-CH2-O), 5.49 (br 
s, 1H, OH), 7.05 (d, J=8.70 Hz, 2H, C2,C6-C6H4), 7.28-7.46 (m, 5H, C6H5), 7.52 
(d, J=8.7, 2H, C3,C5-C6H4), 10.06-10.45 (br s, 1H, NH+)
1.25 (s, 6H, -C(CH3)2), 1.64 (t, J=5,5 Hz, 2H, CH2-CH2-OH), 3.69 (s, 2H, Ar-CH2-
XV 3276 NH), 3.87 (t, J=5.5 Hz, 2H, CH2-CH2-OH), 5.04 (s, 2H, Ar-CH2-O), 6.92 (d, 
J=8.7 Hz, 2H, C2,C6ñC6H4), 7.20-7.41 (m, 7H, Ar: 5H, C6H5, 2H, C3,C5-C6H4)
0.94 (dd, J=6.7 Hz, J=6.9 Hz, 6H, -CH(CH3)2), 1.83-1.90 (m, 1H, -CH(CH3)2), 
2.24 (s, 1H, OH), 2.44-2.49 (m, 1H, NH), 3.34-3.40 (m, 1H, NH-CH), 3.61-3.80 
XVI 3293, 3165
(m, 4H, Ar-CH2, CH2-OH), 5.06 (s, 2H, Ar-CH2-O), 6.94 (d, J=8.5 Hz, 2H, C2,
C6-C6H4), 7.24-7.45 (m, 7H, Ar: 5H, C6H5, 2H, C3,C5-C6H4)
2.57 (t, J = 5.5 Hz, 2H, N-CH2-CH2-OH), 2.51 ñ 2.68 (m, 8H, piperazine), 3,49 
(s, 2H, Ar-CH2-N), 3.63 (t, J = 5.5 Hz, 2H, N-CH2-CH2-OH), 5.09 (s, 2H, 
XVII 3412, 3232
Ar-CH2-O), 6.97 (d, J = 8.5 Hz, 2H, C2,C6-C6H4), 7.24 ñ 7.49 (m, 7H, Ar: 5H, 
C6H5, 2H, C3,C5-C6H4)
154 ANNA M. WASZKIELEWICZ et al.
Table 4. Anticonvulsant activity of the tested compounds [I-XVII] (mice, i.p.).
Dose MES a) ScMet a) Neurotoxicity b)
Compd. mg / kg 0.5 h 4 h 0.5 h 4 h 0.5 h 4 h
30 - - - - - -
I 100 1/3 - - - - -
300 1/1 - 1/1 - 4/4 -
30 - - - - - -
II 100 - - - - - -
300 1/1 - - 1/5 - -
30 - - - - - -
III 100 3/3 - - - -
300 1/1 1/1 - - - -
30 - - - - - -
IV 100 - - - - - -
300 - - 3/5 - 1/4 -
30 - - - - - -
V 100 2/3 - - - - -
300 1/1 - - - 2/4 -
30 - - - - - -
VI 100 3/3 - - - 2/8 -
300 | - | | 3/4 -
30 - - - - - -
VII 100 3/3 - - - 3/8
300 | | | | 4/4 |
30 - - - - - -
VIII 100 3/3 1/3 - - 7/8 2/4
300 | | | | 4/4 |
3 - | | | 1/4 |
10 - | | | - |
IX 30 1/1 - - - 1/4 -
100 3/3 3/3 - - 8/8 1/4
300 | | | | 4/4 |
30 - - 1/5 - - -
X 100 3/3 - 2/5 1/1 6/8 -
300 | | | | 4/4 -
3 - | | | - |
10 - | | | - |
XI 30 1/1 - - - - -
100 3/3 3/3 - - 8/8 -
300 | | | | 4/4 |
30 - - - - - -
XII 100 3/3 1/3 - - 7/8 -
300 | | | | 4/4 |
3 - | | | - |
10 - | | | - |
XIII 30 1/1 - | | 1/4 -
100 3/3 3/3 | | 8/8 1/4
300 | | | | 4/4 |
30 - - - 1/5 2/4 -
XIV 100 3/3 3/3 - - 8/8 3/4
300 | | | | 4/4 |
3 - | | | - |
10 - | | | - |
XV 30 1/1 - - - - -
100 | 1/1 | | 8/8 2/2
300 | | | | 4/4 |
3 - | | | - |
10 - | | | - |
XVI 30 1/1 - - - - -
100 2/2 2/2 | - 8/8 1/3
300 | | | | 4/4 |
30 - - - - - -
XVII 100 3/3 - - - - -
300 1/1 | - | 4/4 |
a) Number of animals protected / number of animals tested; b) number of animals exhibiting toxicity / number of animals tested in the rotorod
test; | indicates that the compound was not tested in the particular case; - indicates that the compound was not active or toxic in the par-
ticular case.
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(12). Isomer III (S) is more active in the MES test
than racemate and II (R), which gave 100% anti-
MES activity in the dose of 300 mg/kg. Of all the
tested amides III seems the most promising, 100%
active in MES without neurotoxicity at the tested
doses. 
Among the tested amines, the most active in
the MES test (mice, i.p.) were IX, XI, XIII, and XV-
XVI as they produced 100% activity at the dose of
30 mg/kg at 0.5 h. Of all the compounds, neurotox-
icity was observed for IX and XIV at the dose of 30
mg/kg, at 0.5 h and it was not revealed for any sub-
stance at 300 mg/kg at 4 h after administration. The
racemate XI and its enantiomer XIII (S) were more
active in the MES test (100% protection at 30
mg/kg) than XII (R) (100% protection at 100
mg/kg). However, the enantiomer XIII exhibited
larger neurotoxicity than its isomer XII and the par-
ent compound XI. Substitution of a secondary
amine [XI] gave XIV and did not increase the anti-
convulsant activity in MES, however, XIV was
active in ScMet. Protective activity in the MES
without neurotoxicity was shown for XI and XV-
XVI (at the dose of 30 mg/kg) and III, V, and XVII
(at the dose of 100 mg/kg). X was also active in the
ScMet (40% protection for 0.5 h and 100% protec-
tion for 4 h at the dose of 100 mg/kg). XIV was
active in the ScMet 4 h after administration (20%
protection) in the dose of 30 mg/kg. At this stage it
seems that among the amines [VI-XVII] XI, XV,
and XVI are the most promising compounds, active
in the MES at the dose of 30 mg/kg and non-toxic at
the doses up to 100 mg/kg. 
Compounds II, III, and V were advanced to the
phase VIa (rats) where III and V revealed 25% activ-
ity in MES (at 1 and 2 h after p.o. administration for
the former and at 0.5 and 1 h after p.o. administration
for the latter) and II was active in ScMet (25% activ-
ity at 1 h after i.p. administration). III was also test-
ed in rats, i.p. (30 mg/kg), where it revealed 50%
activity at 0.25 h, 25% activity at 0.5 h and 50%
activity at 2 h without neurotoxicity. Activity after
1.5 h interval implies that it might be a metabolite to
be active in this case. None of the substances exhib-
ited neurotoxicity in rats, p.o. at the mentioned dose.
The results are presented in Table 5.
Comparing the activity and neurotoxicity
between amides tested [I-V] and published previ-
ously (12) and their amine analogues [VI-XVII], the
achieved results of the preliminary anticonvulsant
tests suggest that the aminoalkanol derivatives [VI-
XVII] are slightly more active in MES and more
neurotoxic comparing to their alkanolamide ana-
logues. On the contrary, the amides reveal stronger
anti-ScMet activity. As both groups of the compared
derivatives (i.e. aminoalkanols and alkanolamides)
reveal anti-Mes and/or anti-ScMet activity, there
exist strong premises for further research in the field
of anticonvulsant activity within both these groups.
As far as the calculated partition coefficient is
considered, its values for compounds I-XVII were
in the range 2.03-2.96 [for amides I-V] and 2.44-
3.41 [for amines VI-XVII] which correspond to the
Log Pcomb. of carbamazepine (CBZ) and valproic acid
(VA) (3.30 and 2.61, respectively) (15). Moreover,
compounds which were advanced to Phase VIa, i.e.
II, III, and V exhibited Log Pcomb. 2.44, 2.44, and
2.68, respectively, which is similar to Log Pcomb. of
the mentioned AEDs, predicting comparable pene-
tration through blood-brain barrier.
Table 5. Anticonvulsant activity of the compounds tested in phase VIa in rats, i.p. [II-III] and rats, p.o. [III, V].
Dose Time in hours 
Compound Test mg/kg 0.25 0.5 1.0 2.0 4.0
MES a) 30 ñ ñ ñ ñ |
II (i.p.) ScMet a) 50 ñ ñ 1/4 ñ ñ
TOX b) 50 ñ ñ ñ ñ ñ
III (p.o.) MES a) 30 ñ ñ 1/4 1/4 ñ
TOX b) 30 ñ ñ ñ ñ ñ
III (i.p.) MES 30 2/4 1/4 ñ 2/4 ñ
TOX 30 ñ ñ ñ ñ ñ
V (p.o.) MES 30 ñ 1/4 1/4 ñ ñ
TOX 30 ñ ñ ñ ñ ñ
a) and b) see Table 3.
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EXPERIMENTAL
Chemistry 
Melting points are uncorrected and were deter-
mined using a B¸chi SMP-20 apparatus. Analyses
of C, H, N were within +/- 0.4% of the theoretical
values. The IR spectra were recorded on a Jasco FT
/ IR 410 spectrometer. The 1H-NMR spectra were
recorded in CDCl3 with a Varian Mercury-VX 300
NMR spectrometer at 29OC. Chemical shifts were
referenced against solvent lock signal. Standard
Varian pulse sequences were used for 2D experi-
ments. Analytical TLC was carried out on precoated
plates (silica gel, 60 F-254 Merck) using the solvent
system (methanol / ethyl acetate (1:1, v/v)); spots
were visualized with UV light. Measurements of
optical rotation ([α]589 and [α]546) were carried out
using Jasco DIP-1000 (λ = D (589 nm)) and Polamat
A (Carl Zeiss, Jena) (λ = 546). Enantiomeric 2-
amino-1-butanols ([α]20546: (R) = -11.25O; (S) =
+11.15o) were obtained earlier (11). The reagent: 4-
(benzyloxy)benzylalcohol was purchased from
Lancaster, other reagents and solvents were com-
mercially available materials of reagent grade. The
theoretical values of log Pcomb. (partition coefficient)
of synthesized structures and comparative AEDs
were calculated with the use of PALLAS 3.1.1.2
program. 
General procedure for synthesis of I-V:
A mixture of 0.01 mole of appropriate
aminoalkanols with 0.025 mole K2CO3 in 15 cm3 of
water and 15 cm3 of toluene was cooled to 10-12OC.
After cooling, a solution of 0.011 mole of 4-(benzy-
loxy)benzoyl chloride in 30 cm3 of dry toluene was
added under vigorous stirring at 10-12OC for 0.5 h.
Then the reaction mixture was heated at 50OC and
then left to cool down. The precipitated amide
deposit was filtered off, stirred with a 10% solution
of NaHCO3, and after drying recrystallized from a
mixture of toluene/heptane (1:1, v/v).
General procedure for synthesis of VII, XII-XIII,
and XV-XVI:
A solution of 0.002 mole of appropriate [4-
(benzyloxy)benzoyl]-aminoalkanol in dried and
fresh distilled diethyl ether was cooled to 0OC under
nitrogen. Then 1.2 cm3 of 1 M solution of LiAlH4
was added dropwise and the mixture was stirred for
12 h at room temperature. The reaction was
quenched by adding 2 cm3 of 15% NaOH. The
organic phase was separated, the residue was
extracted with diethyl ether, and dried over K2CO3,
filtered and the solvent was removed in vacuum.
The obtained compounds [VII, XII-XIII, and XV-
XVI] were purified using planar circular chro-
matography (chromatotron) and recrystallized from
n-heptane.
General procedure for synthesis of VI, VIII-XI,
and XVII:
A mixture of 0.01 mole of an appropriate
aminoalkanol with 0.01 mole of 4-(benzyloxy)ben-
zyl chloride in 30 cm3 of toluene was refluxed in the
presence of 0.01 mole of K2CO3 for 6 h. Inorganic
salts were filtered off from the hot mixture and
washed with hot toluene (5 cm3). The solvent was
distilled off from the filtrate under reduced pressure.
After addition of n-heptane (for bases) or ethanol
saturated with HCl (for hydrochlorides) to the
residue, the mixture was refluxed and cooled. The
crystals formed were collected by filtration and
dried. Recrystallization from n-heptane (for bases)
gave VI base, VIII base, IX-XI, and XVII and
from ethanol with small amount of acetone gave VI,
VIII, XIa, and XVII.
Pharmacology
Initial evaluations for anticonvulsant activity
were carried out by the ASP, which consisted of ini-
tial evaluations of anticonvulsant activity and
included Phase I and VIa tests procedures. These
screens were performed either in male Carworth
Farms no. 1 (CF 1) mice (18-25 g) or male Sprague-
Dawley rats (100-150 g). In the phase I studies
which deal with qualitative assay, all the compounds
were tested for activity in MES and ScMet tests as
well as in the rotorod screen for TOX. The examined
compounds were suspended in 0.5% aq. methylcel-
lulose and were administered at three dosage levels
(30, 100 and 300 mg/kg) with anticonvulsant activi-
ty noted 0.5 and 4 h after i.p. administration in mice.
Phase VIa was a similar qualitative evaluation to the
Phase I evaluation, but the test drug was examined
for an oral activity in the rats utilizing the three
screens noted previously. The details of these proce-
dures have been published (13, 14). The Phase I and
VIa tests results are listed in Table 4 and 5, respec-
tively.
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